nivolumab,cc-122,cetuximab,cc-99282,durvalumab,ibrutinib,cc-220,relatlimab
janssen,astrazeneca,abbvie,bms,eli lilly,i-mab
['cetuximab', 'platform', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'imab ']
 platform-b study final results in 1stl raswt mcrc ctdna ngs combined analysis of trunk and resistant mutations after only 2 cycles of ct+cetuximab is the best predictor of response to treatment. #ttdupdates #crc (2/3) 
TTD Group-Grupo Español de Tratamiento de los Tumores Digestivos. Fomentamos la investigación clínica, traslacional y epidemiológica de los cánceres digestivos